ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

PBX Probiotix Health Plc

4.25
0.00 (0.00%)
24 May 2024 - Closed
Realtime Data
Share Name Share Symbol Market Type Share ISIN Share Description
Probiotix Health Plc AQSE:PBX Aquis Stock Exchange Ordinary Share GB00BLNBFR86
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 4.25 3.00 6.00 4.50 4.25 4.25 0.00 16:29:55
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Probiotix Health PLC Directorate Change (2910Z)

11/01/2024 7:00am

UK Regulatory


Probiotix Health (AQSE:PBX)
Historical Stock Chart


From Nov 2023 to May 2024

Click Here for more Probiotix Health Charts.

TIDMPBX

RNS Number : 2910Z

Probiotix Health PLC

11 January 2024

ProBiotix Health plc

( "ProBiotix" or the "Company")

Directorate change

ProBiotix Health p lc (AQUIS: PBX), a life sciences busi ness d eveloping probiotics to support cardiometabolic health, announces that Mikkel Hvid-Hansen, Commercial Director and Board member of the Company, has resigned from his position to pursue other opportunities, effective from 28 February 2024.

Separately, the Company announces the appointment of Michael Litichevski as Head of Global Sales as of 1 January 2024. The appointment of Michael is part of the Company's strategy to build a strong commercial team to support the long-term growth of ProBiotix. Michael joins ProBiotix from Lactobio, a microbial solutions and microbiome skincare company with a live bacteria business. He has over 25 years' experience in building B2B segments with more than 11 years of this specifically within the probiotics dietary supplements industry. He was previously VP of Sales at Deerland Probiotics & Enzymes, VP sales of Bifodan and has worked for large organisations such as Orkla brands and Nycomed. Michael has e xtensive experience with the commercialisation of innovative and high-quality probiotic solutions which is in line with the Company's strategical direction of finished supplement dosage format. He has good connections in the industry and has the ability to create strong and valuable partnerships.

Steen Andersen, CEO of ProBiotix Health plc commented: "We are sad to see Mikkel leave us but wish him well in his future endeavours. He has held the role of European Sales Director and Commercial Director at ProBiotix for the last four years, since before we listed on Aquis, and has brought a wealth of knowledge and expertise to the role. The Board would like to thank him for his service and guidance.

"We would also like to extend a warm welcome to Michael as our new Head of Global Sales. I am confident that he will be a huge asset to the commercial team and will greatly contribute to building our B2B business both locally and globally. He b rings vast experience in sales leadership combined with scientific knowledge from global leading probiotic companies to support ProBiotix's strategy and sales on an international level. "

For further information, please contact:

 
 ProBiotix Health plc                          https://probiotixhealth-ir.com/ 
 Steen Andersen, Chief Executive                          Contact via Walbrook 
                                                                         below 
 
 Peterhouse Capital Limited (Aquis Corporate                Tel: 020 7469 0930 
  Adviser and Broker) 
 Mark Anwyl 
 Duncan Vasey 
 
 Walbrook PR Ltd                                      probiotix@walbrookpr.com 
 Anna Dunphy                                                Mob: 07876 741 001 
 

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms part of retained EU law (as defined in the European Union (Withdrawal) Act 2018).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NEXEALFEFFDLEFA

(END) Dow Jones Newswires

January 11, 2024 02:00 ET (07:00 GMT)

1 Year Probiotix Health Chart

1 Year Probiotix Health Chart

1 Month Probiotix Health Chart

1 Month Probiotix Health Chart

Your Recent History

Delayed Upgrade Clock